DrugBiological
Teprotumumab clinical trials
Also written TEPEZZA, HZN-001 and RG1507.
- studies test it
- 19
- open now
- 2
- in phase 3
- 3
- first study started
- 2006
Keep track of what changes. Save the teprotumumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 4
- Phase 3
- 3
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 2
Amgen (11) · Hoffmann-La Roche (6) · Sun Yat-sen University (1) · Sheba Medical Center (1)
Often tested with
Tested in the same studies.
Erlotinib (2) · RO1507 (1) · Bevacizumab (1) · Capecitabine (1) · Carboplatin (1) · Cetuximab (1) · Docetaxel (1) · Etoposide (1)
Studies
Open first, then newest update. How each study uses teprotumumab is read from its arms, and is right about nine times in ten.
Testing it · 19
- Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic NeuropathyNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07594912Written as Teprotumumab N01
- Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye DiseaseNot yet recruitingPhase 4Sheba Medical CenterNCT07308964Written as Teprotumumab Injection [Tepezza]
- TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement StudyCompletedPhase 4AmgenNCT05002998Written as Teprotumumab
- A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye DiseaseActive, not recruitingPhase 3AmgenNCT06248619Written as Teprotumumab
- A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese ParticipantsCompletedPhase 1AmgenNCT07142642Written as Teprotumumab
- A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)CompletedPhase 1AmgenNCT02103283Written as Teprotumumab
- Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye DiseaseCompletedPhase 2AmgenNCT01868997Written as teprotumumab
- A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese ParticipantsCompletedPhase 1AmgenNCT06674941Written as Teprotumumab
- Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical StudyCompletedPhase 3AmgenNCT03298867Written as Teprotumumab
- A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseaseCompletedPhase 4AmgenNCT04583735Written as TEPEZZA
- Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension StudyCompletedPhase 3AmgenNCT03461211Written as Teprotumumab
- A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)TerminatedPhase 1AmgenNCT04478994Written as TEPEZZA
- A Study of TEPEZZA® Treatment in Participants With Thyroid Eye DiseaseCompletedPhase 1AmgenNCT06389578Written as Teprotumumab
- A Study of R1507 in Participants With Recurrent or Refractory SarcomaTerminatedPhase 2Hoffmann-La RocheNCT00642941Written as RG1507
- A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast CancerCompletedPhase 1Hoffmann-La RocheNCT00882674Written as RG1507
- A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.CompletedPhase 1Hoffmann-La RocheNCT00400361Written as RG1507
- A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid TumorsTerminatedPhase 1Hoffmann-La RocheNCT00811993Written as RG1507
- A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.CompletedPhase 1Hoffmann-La RocheNCT00560144Written as RG1507
- A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.TerminatedPhase 2Hoffmann-La RocheNCT00773383Written as RG1507
Given in every arm · 4 — teprotumumab is usual care beside what is tested
- A Study of TEPEZZA Subcutaneous Administration in Healthy AdultsCompletedPhase 1AmgenNCT06563856Written as TEPEZZA
- A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).TerminatedPhase 2Hoffmann-La RocheNCT00760929Written as RG1507
- A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast CancerTerminatedPhase 2Hoffmann-La RocheNCT00796107Written as RG1507
- A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid TumorsTerminatedPhase 1Hoffmann-La RocheNCT00985374Written as RG1507
Codes
What other systems call teprotumumab · ClinicalTrials.gg INT005679
- MeSH (NLM) C551399teprotumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) Y64GQ0KC0ATEPROTUMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2274803One source FDA
- Wikidata Q7701391teprotumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95797TeprotumumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C551399 | teprotumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | Y64GQ0KC0A | TEPROTUMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2274803 | — | One source FDA |
| Wikidata | Q7701391 | teprotumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95797 | Teprotumumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.